ArticleBritish journal of cancer2018

A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424.

Victoria K Woodcock et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.